Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2023-04-03 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
独立董事关于续聘2023年度审计机构的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from independent directors regarding the prior approval for the reappointment of the audit firm for the 2023 fiscal year. It references the upcoming board meeting to discuss the reappointment of the audit firm. The document is short (549 characters) and does not contain any financial data or audit results itself. It is essentially an opinion or approval statement related to audit firm reappointment, not the audit report or annual report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit matters but is not a full annual report or audit report. Confidence is high given the clear context and content. FY 2023
2023-04-03 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司使用部分闲置募集资金及自有资金进行现金管理的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from the sponsor institution (长城证券股份有限公司) regarding the use of idle raised funds and own funds by 浙江泰林生物技术股份有限公司 for cash management. It includes information about the fundraising, approval procedures, risk control measures, and compliance with regulatory requirements. The document is not a financial report itself but a regulatory compliance and verification statement related to the use of funds. It does not contain financial statements or earnings data. The length is 4365 characters, which is relatively short and the document is more of a regulatory compliance and verification report rather than a full financial report or announcement. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification document related to fundraising and fund usage.
2023-04-03 Chinese
关于变更注册资本并修订公司章程的公告
Share Issue/Capital Change Classification · 95% confidence The document is an announcement from Zhejiang Tailin Biotechnology Co., Ltd. regarding changes in registered capital and amendments to the company's articles of association. It details the conversion of convertible bonds into shares, capital increase from capital reserve, and the corresponding changes in registered capital and share capital. It also mentions the board meeting resolutions and the need for shareholder approval. The document is a formal announcement of corporate actions related to capital changes and amendments to the company charter, not a full financial report or detailed presentation. It fits the category of Share Issue/Capital Change (SHA) because it involves changes in registered capital and share capital structure.
2023-04-03 Chinese
2022年度监事会工作报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to the "2022 Supervisory Board Work Report" of Zhejiang Tailin Biotechnology Co., Ltd. It details the supervisory board's activities, oversight of financial conditions, internal controls, compliance with laws and regulations, and review of the 2022 annual report. It includes summaries of meetings held, audit supervision, internal control evaluations, and compliance with disclosure requirements. The document is a detailed report on the supervisory board's work and oversight for the year 2022, not the annual report itself, nor an announcement or certification. It is a standalone audit-related supervisory report focusing on oversight and audit activities, fitting the category of Audit Report / Information (AR). The document length is 3589 characters, which is relatively short but contains substantive supervisory content rather than just an announcement or certification. Therefore, the best classification is AR with high confidence. FY 2022
2023-04-03 Chinese
召开2022年度网上业绩说明会的提示性公告
Investor Presentation Classification · 95% confidence The document is an announcement about the scheduling of an online performance explanation meeting (业绩说明会) for the fiscal year 2022, to be held on April 13, 2023. It invites investors to participate and submit questions in advance. The document does not contain actual financial statements or detailed financial analysis but rather serves as a notice for an upcoming event where financial results will be discussed. The document length is short (699 characters), and it is clearly an announcement rather than the report or transcript itself. Therefore, it fits best under the category of Investor Presentation (IP), as it relates to a detailed presentation for investors focusing on financials and company performance, even though the actual presentation will occur later. It is not a full transcript (CT) or an annual report (10-K).
2023-04-03 Chinese
2022年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2022 年度内部控制自我评价报告' which translates to '2022 Annual Internal Control Self-Evaluation Report'. It is issued by the company's board and discusses the internal control evaluation for the fiscal year ending December 31, 2022. The content includes detailed descriptions of internal control structures, evaluation methods, defect classifications, and conclusions about the effectiveness of internal controls. It references regulatory frameworks and standards related to internal control but does not contain financial statements or earnings data. The document is a standalone internal control audit/self-evaluation report rather than a full annual report or earnings release. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and internal control evaluations. FY 2022
2023-04-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.